No increase in sexual risk-taking seen in partners who know they are protected from HIV transmission

October 16, 2013

HIV-negative partners in heterosexual serodiscordant couples who use prophylactic drugs to protect against HIV transmission do not show any significant increase in risky sexual behaviour, even when they know they are protected, according to new results published in The Lancet Infectious Diseases.

An international team of researchers, led by Dr Jared Baeten of the University of Washington, in Seattle, USA, used findings from the Partners PrEP study – which in 2011 established for the first time that pre-exposure could protect HIV-negative men and women in serodiscordant couples from HIV transmission – to determine whether people's knowledge that they were protected from HIV by the regimen affected the sexual behaviour of HIV-negative partners.

"Evidence for the effectiveness of new HIV prevention strategies, including pre-exposure prophylaxis, has spurred optimism that the global HIV epidemic might be reversed," says Dr Baeten. "However, an important question is whether HIV-negative partners who know they're protected by prophylaxis will compensate for this by increasing their sexual risk-taking, such as through increasing their levels of ."

The researchers analysed data on over 3000 study participants, for up to 12 months before and 12 months after the protective effects of pre-exposure prophylaxis were demonstrated in the study. In addition to receiving prophylactic drugs, all study participants underwent risk-reduction counselling, safety monitoring, pregnancy testing, and tests for the sexually transmitted infections gonorrhoea, chlamydia, and trichomoniasis.

Once the protective effects of pre-exposure prophylaxis were established in 2011, the trial results were disseminated to study participants and their participation in the research continued thereafter.

After the results were revealed to study participants, the researchers found no significant difference in the level of unprotected sex taking place between partners.

Before the study results were revealed, the researchers had already noted a gradually decreasing trend in the frequency of unprotected sex, suggesting that the risk counselling and other measures provided as part of the study may have been effective; this trend did not change after became aware that pre-exposure prophylaxis provided protection from HIV transmission.

The findings did show a small, but significant increase in the frequency of unprotected sex outside the study partnership after the findings were unmasked, although this increase was relatively small and was not accompanied by increasing rates of STI infection or pregnancy.

According to Dr Baeten, "To our knowledge, this study provides the first empirical data on in heterosexual people receiving open-label oral pre-exposure prophylaxis for HIV prevention. The results provide encouraging evidence that behavioural changes as a result of pre-exposure prophylaxis might not undermine its strong HIV prevention and public health benefits."

In a linked Comment, Dr Kristen Underhill and Dr Kenneth Mayer write that, "The Partners PrEP analysis provides an important advance in the measurement of behaviour among serodiscordant couples using pre-exposure prophylaxis. Future research should examine the behaviours of pre-exposure prophylaxis users outside trial settings, behavioural strategies for optimisation of pre-exposure prophylaxis uptake and adherence while decreasing risk-taking, methods for assessment of users' behaviours over time, and methods for training providers. Researchers and implementers should also investigate the context of behaviour among pre-exposure prophylaxis users; individuals might have personally meaningful reasons to take risks, such as fertility desires, and understanding these motivations can strengthen efforts to support pre-exposure prophylaxis users before, during, and after use."

Explore further: Preventing HIV infection with anti-HIV drugs in people at risk is cost-effective

More information: … (13)70226-3/abstract

Related Stories

Preventing HIV infection with anti-HIV drugs in people at risk is cost-effective

March 12, 2013
An HIV prevention strategy in which people at risk of becoming exposed to HIV take antiretroviral drugs to reduce their chance of becoming infected (often referred to as pre-exposure prophylaxis or PrEP), may be a cost-effective ...

Effectiveness of HIV pre-exposure prophylaxis in Peru

October 9, 2012
In this week's PLOS Medicine, Anna Borquez from Imperial College London and an international group of authors developed a mathematical model representing the HIV epidemic among men who have sex with men (MSM) and transwomen ...

Antiretroviral treatment for preventing HIV infection: an evidence review for physicians

May 28, 2012
While immediate postexposure treatment for suspected HIV is critical, pre-exposure preventive treatment is a newer method that may be effective for people in high-risk groups, states a review of evidence published in CMAJ ...

Drugs used to treat HIV also reduce risk of HIV infection

July 10, 2012
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers ...

Pills to prevent HIV raise many questions: studies

July 11, 2012
Various trials examining the use of anti-retroviral drugs in healthy heterosexuals as a way to prevent HIV have shown drastically different results, research showed Wednesday.

Hope for more options in couples where one partner is HIV positive

November 15, 2011
In sub-Saharan Africa, couples in long-term relationships where one partner is HIV-positive and the other is HIV-negative (HIV serodiscordant couples) could benefit from anti-AIDS drugs (antiretroviral therapy) given either ...

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.